Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PhytoTech Therapeutics developed advanced oral delivery systems for cannabinoid-based prescription drugs using a proprietary lipid nano technology licensed from Yissum Research Development Company of Hebrew University. The company completed clinical trials including a Phase II study of PTL101 (oral cannabidiol capsules) as adjunctive treatment for pediatric intractable epilepsy and a Phase I pharmacokinetic/safety study comparing novel THC/CBD capsules to Sativex®. The company was acquired by Harvest One Cannabis Inc. via MMJ Group Holdings Limited in late 2018 and does not appear to be active as an independent entity since then[3][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PhytoTech Therapeutics.